We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to...
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Paris, le 19 décembre 2024. Le Conseil...
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Duvakitug positive phase 2b results demonstrate best-in-class...
Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de...
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the...
Press Release: Availability of the Q4 2024 Aide-mémoire Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024. Sanofi announced today that its Q4 2024 Aide-mémoire is...
Communiqué de presse : Mise en ligne du document « Q4 2024 Aide-mémoire » Mise en ligne du document « Q4 2024 Aide-mémoire » Paris, France, le 17 Décembre 2024. Sanofi annonce la mise en ligne...
Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024. Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website:...
Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées Le...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.86 | 0.951117009511 | 90.42 | 93.29 | 87.5 | 2364130 | 90.79275156 | DE |
4 | -0.52 | -0.566448801743 | 91.8 | 93.42 | 87.5 | 1618973 | 91.52573691 | DE |
12 | -10.54 | -10.3516008643 | 101.82 | 104.46 | 87.5 | 1534807 | 95.69159524 | DE |
26 | 4.26 | 4.89542633877 | 87.02 | 106.14 | 86.71 | 1519117 | 96.40787764 | DE |
52 | 2.17 | 2.43519245876 | 89.11 | 106.14 | 84.93 | 1443789 | 93.29333152 | DE |
156 | 5.62 | 6.56082185384 | 85.66 | 106.66 | 76.45 | 1737311 | 92.71328949 | DE |
260 | 1.18 | 1.30965593785 | 90.1 | 106.66 | 67.65 | 1943101 | 89.40337895 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions